GTX Corp Announces Symposium and Presentation of Data on Muscle Wasting in Non-Small Cell Lung Cancer Patients
Published: Sep 17, 2012
MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced today that it is sponsoring a symposium on Muscle Wasting in Non-Small Cell Lung Cancer Patients at 12:00 pm eastern daylight time on September 22, 2012, at the Hilton Back Bay Hotel in Boston Massachusetts. Stefan Anker, MD, PhD will introduce an esteemed faculty of experts, including Jeffrey Crawford, MD, Carla Prado, PhD, Richard Gralla, MD, and James D. Dalton, PhD, who will discuss muscle wasting in lung cancer patients and the role of patients’ quality of life when addressing cancer care. The science behind using selective androgen receptor modulators (SARMs) to address muscle wasting in cancer patients will be presented, as well as GTx’s clinical trial design for its ongoing pivotal Phase III clinical trials of enobosarm (a SARM developed by GTx) for the prevention and treatment of muscle wasting in non-small cell lung cancer patients.